Pfizer earnings: Looking toward an ambitious 2022 agenda By: MarketWatch October 29, 2018 at 10:47 AM EDT Pfizer plans to have up to 30 new drug approvals in the coming years, to make up for losing patent protection on a number of valuable products. Read More >> Related Stocks: Eli Lilly Pfizer S&P Biotech SPDR S&P Pharmaceuticals SPDR